SpyGlass Pharma, Inc. Common Stock
SGPHealthcare|Biotechnology|US
$36.95
+2.87 (+8.41%)
DCF Value
$2.90
Tangible Book / Share
$6.95
Cash / Share
$7.00
Ownership Breakdown
41.8%
Float
33.4M
Shares Outstanding
14.0M
Float Shares
Major Holders (38)
Combined: 529.6%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Rajeev Shah | HC, IN | 24.10% | 8,022,639 | Feb 17, 2026 | 13D/G |
| RA Capital Management, L.P. | IA, PN | 24.10% | 8,022,639 | Feb 17, 2026 | 13D/G |
| Peter Kolchinsky | HC, IN | 24.10% | 8,022,639 | Feb 17, 2026 | 13D/G |
| Mohamad H. Makhzoumi | Individual | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| Scott D. Sandell | Individual | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| Paul Walker | Individual | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| New Enterprise Associates 17, L.P. | Partnership | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| NEA Partners 17, L.P. | Partnership | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| Nea 17 GP, LLC | Other | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| New Enterprise Associates 16, L.P. | Partnership | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| NEA Partners 16, L.P. | Partnership | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| Nea 16 GP, LLC | Other | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| Forest Baskett | Individual | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| Ali Behbahani | Individual | 22.20% | 7,393,823 | Feb 13, 2026 | 13D/G |
| Carmen Chang | Individual | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| Anthony A. Florence, Jr. | Individual | 22.20% | 7,392,301 | Feb 13, 2026 | 13D/G |
| Edward T. Mathers | Individual | 18.10% | 6,035,038 | Feb 13, 2026 | 13D/G |
| Rick Yang | Individual | 18.10% | 6,035,038 | Feb 13, 2026 | 13D/G |
| RA Capital Healthcare Fund, L.P. | Partnership | 17.90% | 5,966,439 | Feb 17, 2026 | 13D/G |
| Peter Justin Klein | Individual | 9.90% | 3,310,619 | Feb 10, 2026 | 13D/G |
| Kirk Nielsen | Individual | 9.90% | 3,312,141 | Feb 10, 2026 | 13D/G |
| Vensana Capital I, L.P. | Partnership | 9.90% | 3,310,619 | Feb 10, 2026 | 13D/G |
| Vensana Capital I GP, LLC | Other | 9.90% | 3,310,619 | Feb 10, 2026 | 13D/G |
| Sands Frank M. | HC, IN | 7.80% | 2,500,012 | Feb 13, 2026 | 13D/G |
| Gilde Healthcare VG VI Management B.V. | Other | 6.57% | 2,187,513 | Feb 13, 2026 | 13D/G |
| Cooperatieve Gilde Healthcare VG VI U.A. | Other | 6.57% | 2,187,513 | Feb 13, 2026 | 13D/G |
| Manapouri B.V. | Other | 6.57% | 2,187,513 | Feb 13, 2026 | 13D/G |
| Martemanshurk B.V. | Other | 6.57% | 2,187,513 | Feb 13, 2026 | 13D/G |
| Gilde Healthcare Holding B.V. | Other | 6.57% | 2,187,513 | Feb 13, 2026 | 13D/G |
| Sands Capital Life Sciences Pulse Fund III-Holdings, L.P. | Partnership | 6.50% | 2,079,215 | Feb 13, 2026 | 13D/G |
| Srinivas Akkaraju | Individual | 6.30% | 2,109,953 | Feb 17, 2026 | 13D/G |
| RA Capital Nexus Fund III, L.P. | Partnership | 6.20% | 2,054,678 | Feb 17, 2026 | 13D/G |
| Samsara BioCapital, L.P. | Partnership | 4.50% | 1,484,953 | Feb 17, 2026 | 13D/G |
| Samsara BioCapital GP, LLC | Other | 4.50% | 1,484,953 | Feb 17, 2026 | 13D/G |
| Samsara Opportunity Fund, L.P. | Partnership | 1.90% | 625,000 | Feb 17, 2026 | 13D/G |
| Samsara Opportunity Fund GP, LLC | Other | 1.90% | 625,000 | Feb 17, 2026 | 13D/G |
| Sands Capital Life Sciences Pulse Fund III (DE), L.P. | Partnership | 1.30% | 420,797 | Feb 13, 2026 | 13D/G |
| Sands Capital Alternatives, LLC | Other | 1.30% | 420,797 | Feb 13, 2026 | 13D/G |